These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 24500767)
1. A bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) complex with anticancer action upon photodeprotection. Joshi T; Pierroz V; Mari C; Gemperle L; Ferrari S; Gasser G Angew Chem Int Ed Engl; 2014 Mar; 53(11):2960-3. PubMed ID: 24500767 [TBL] [Abstract][Full Text] [Related]
2. Bis(dipyridophenazine)(2-(2'-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) hexafluorophosphate: a lesson in stubbornness. Joshi T; Pierroz V; Ferrari S; Gasser G ChemMedChem; 2014 Jul; 9(7):1419-27. PubMed ID: 24591361 [TBL] [Abstract][Full Text] [Related]
3. Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent. Wei J; Renfrew AK J Inorg Biochem; 2018 Feb; 179():146-153. PubMed ID: 29180165 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, spectroscopic properties, and photoinduced CO-release studies of functionalized ruthenium(II) polypyridyl complexes: versatile building blocks for development of CORM-peptide nucleic acid bioconjugates. Bischof C; Joshi T; Dimri A; Spiccia L; Schatzschneider U Inorg Chem; 2013 Aug; 52(16):9297-308. PubMed ID: 23919761 [TBL] [Abstract][Full Text] [Related]
5. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells. Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344 [TBL] [Abstract][Full Text] [Related]
6. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug. Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Medicinal Potential of Two Ruthenium(II) Polypyridine Complexes as One- and Two-Photon Photodynamic Therapy Photosensitizers. Hess J; Huang H; Kaiser A; Pierroz V; Blacque O; Chao H; Gasser G Chemistry; 2017 Jul; 23(41):9888-9896. PubMed ID: 28509422 [TBL] [Abstract][Full Text] [Related]
12. Influence of carboxylic acid functionalities in ruthenium (II) polypyridyl complexes on DNA binding, cytotoxicity and antioxidant activity: synthesis, structure and in vitro anticancer activity. Sathiya Kamatchi T; Chitrapriya N; Kim SK; Fronczek FR; Natarajan K Eur J Med Chem; 2013 Jan; 59():253-64. PubMed ID: 23234855 [TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid. Pierroz V; Joshi T; Leonidova A; Mari C; Schur J; Ott I; Spiccia L; Ferrari S; Gasser G J Am Chem Soc; 2012 Dec; 134(50):20376-87. PubMed ID: 23181418 [TBL] [Abstract][Full Text] [Related]
14. A ruthenium(II) arene complex showing emission enhancement and photocleavage activity towards DNA from singlet and triplet excited states respectively. Chen Y; Lei W; Jiang G; Zhou Q; Hou Y; Li C; Zhang B; Wang X Dalton Trans; 2013 Apr; 42(16):5924-31. PubMed ID: 23459918 [TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of opened arene ruthenium metalla-assemblies. Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944 [TBL] [Abstract][Full Text] [Related]
16. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates. Notaro A; Gasser G Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562 [TBL] [Abstract][Full Text] [Related]
17. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis. Ma L; Ma R; Wang Z; Yiu SM; Zhu G Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281 [TBL] [Abstract][Full Text] [Related]
18. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione. Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and Biological Evaluation of Ru(II) and Pt(II) Complexes Bearing Carboxyl Groups as Potential Anticancer Targeted Drugs. Martínez MÁ; Carranza MP; Massaguer A; Santos L; Organero JA; Aliende C; de Llorens R; Ng-Choi I; Feliu L; Planas M; Rodríguez AM; Manzano BR; Espino G; Jalón FA Inorg Chem; 2017 Nov; 56(22):13679-13696. PubMed ID: 29099179 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties. Fandzloch M; Dobrzańska L; Jędrzejewski T; Jezierska J; Wiśniewska J; Łakomska I J Biol Inorg Chem; 2020 Feb; 25(1):109-124. PubMed ID: 31741123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]